Clarity AI Announces Partnership With Aspiration to Deliver Data-Led Climate and Impact Solutions for Consumer Platforms, as Consumer Demand for Sustainability Grows
26.7.2023 15:00:00 EEST | Business Wire | Press release
Clarity AI, the leading sustainability tech platform announces it has partnered with Aspiration, a top global climate finance company, to launch sustainability assessment solutions for consumer use cases. This unique partnership will deliver effective and accessible solutions to consumer platforms (e.g. e-commerce, retail banks, supermarkets, etc.) to help end users measure and reduce their carbon footprint and understand the sustainability performance of merchants by combining Clarity AI’s high-quality, transparent data and tools with Aspiration’s best-in-class carbon removal projects.
How the climate solution works
Customers will be able to assess the sustainability of the brands they buy and their current spending habits based on Clarity AI’s personalized data tracking and AI capabilities – helping them to identify ways to positively change their purchasing patterns.
Clarity AI’s technology will also provide sustainability insights at the individual retailer level. Leveraging its coverage of over 40,000 companies and more than 160 industries (the broadest in the market), Clarity AI calculates the impact of a consumer’s spending and helps them understand company-specific sustainability information rather than broad, industry-level spending trends. It also provides recommendations on how consumers can maximize the impact of their purchases and actions.
Based on this data, Aspiration will offer customers the opportunity to mitigate their carbon footprint by purchasing credits from high-quality, nature-based climate solutions that are rigorously vetted to deliver real, tangible impact that contributes toward the path to net zero.
Aspiration will also offer customers the opportunity to contribute to carbon removal projects with benefits beyond climate impact such as biodiversity improvements and job creation for underrepresented communities. This approach allows users to support projects that align with their values in broader environmental and social dimensions.
High customer demand for carbon data on purchases and mitigation strategies can be met with high-quality carbon credits
During a recent Clarity AI-hosted event for over 900 global brands (including Citigroup, eBay, and Target), companies revealed which sustainability metrics were most important to their customers.
Amongst the food and beverage, fashion, and electronics sectors – which accounted for 65% of responses – carbon emissions were the most critical metric, with 60% of respondents saying that their customers wanted to see this information. Additionally, 87% of attendees believed sustainability information about consumers’ purchases will be a must-have before 2030, with 44% of them believing it will be a must-have by 2025.
This consumer demand for quality sustainability information is increasing in line with the number of tools available to support sustainability projects, including carbon removals – between 2020 and 2021 the carbon market saw year-on-year growth of 164%.
However, rigorous quality control is critical to driving impact. Aspiration implements best-in-class standards when it comes to vetting carbon removal and avoidance projects – on average, less than one in five projects Aspiration reviews through its diligence process make it into its pipeline of approved projects.
This solution from Clarity AI and Aspiration aims to empower customers to understand the impact of their purchasing decisions and the opportunity for them to take effective action.
Rebeca Minguela, Founder & CEO of Clarity AI commented: “We believe that customers need and want to act, and they need data and tools to do so. They need to seamlessly see the carbon footprint of their purchases and trust that information. Then they need to easily offset those and get recommendations on how to maximize their impact going forward. Partnering with Aspiration, we can satisfy all those criteria and help consumers find a path to a more sustainable future.”
Olivia Albrecht, CEO of Aspiration commented: “The best way to transition to a low-carbon economy is for businesses, consumers, and communities to work collectively to achieve climate goals. The solution we're providing through our collaboration with Clarity AI is all about giving consumers access to climate data and the tools to take action right at their fingertips via their mobile apps.”
About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. Clarity AI’s capabilities are an essential tool for end-to-end sustainability analysis related to investing, corporate research, benchmarking, consumer e-commerce, and regulatory reporting. As of June 2023, Clarity AI’s platform analyzes more than 70,000 companies, 420,000 funds, 201 countries, and 199 local governments, which represents more breadth than any other player in the market. One way Clarity AI delivers on its mission to bring societal impact to markets is by ensuring its capabilities are delivered directly into clients' workflows through integrations with partners like BlackRock - Aladdin, Refinitiv an LSEG business, BNP Manaos, CACEIS, and SimCorp. Additionally, Clarity AI's sustainability insights reach more than 150 million consumers across more than 400,000 merchants. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets and includes companies like Invesco, Nordea, BlackRock, Santander, Wellington, and BNP Paribas.
About Aspiration
Aspiration Partners is a high-impact climate finance company working at scale to help enterprises, consumers, and investors achieve their climate goals. Founded in 2013, the company sources, monitors, and invests in carbon removal projects across the globe to generate high-quality carbon credits. Every project in Aspiration's portfolio is held to the most rigorous standards, ensuring each drives tangible, positive impact for people and the planet. Aspiration is a certified B Corp, a member of Project Drawdown, 1t.org, Climate Pledge and many other critical industry groups dedicated to accelerating climate action. For more information, visit Aspiration.com or Aspiration.com/business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726278134/en/
Contact information
Media Contact
Edelman
clarityAI@edelmansmithfield.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
